| Literature DB >> 25861244 |
Yifan Sun1, Yu Lu1, Li Xie1, Yan Deng1, Shan Li1, Xue Qin1.
Abstract
BACKGROUND: Previous studies proved that interferon gamma (IFN-γ) gene polymorphisms were associated with the risk of hepatitis B virus (HBV) infection. However, the association between IFN-γ polymorphisms and HBV-related liver cirrhosis (HBV-LC) risk is still unclear.Entities:
Keywords: Hepatitis B virus; Interferon gamma; Polymorphisms
Year: 2015 PMID: 25861244 PMCID: PMC4389711 DOI: 10.1186/s12935-015-0184-2
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
The primer sequences and reaction conditions
|
|
|
|
|
|
|---|---|---|---|---|
| +874 T/A | T allele primer: 5′-TTCTTACAACACAAATACAATACT-3′ | 61°C,56°C | SSP-PCR | AA,AT,TT:303 |
| (rs2430561) | A allele primer: 5′-TTCTTACAACACAAATACAATACA-3′ | |||
| common primer: 5′-TCCCATATAAACCTATAATATGCA-3′ | ||||
| inner reference F: 5′-CTTCAACACCCCAGCCTAGTAC-3′ | Inner reference: 400 | |||
| inner reference R: 5′-CCTCAGGGCAGCGAGACC-3′ | ||||
| +2109A/G (rs1861494) | F: 5′-GAGAGGTAAGGTGAGAGAGAACC-3′ | 55°C | RFLP-PCR (MspI) | AA:267 |
| R: 5′-AGCAAAGAAGGTCTACAAACT-3′ | AG:267 + 245 + 22 | |||
| GG:245 + 22 |
SSP-PCR,sequence-specific primer-polymerase chain reaction; RFLP-PCR, polymerase chain reaction-restriction fragment length polymorphism.
The basic characters of the study population
|
|
|
|
|
|
|---|---|---|---|---|
|
|
|
| ||
|
| 37.78 ± 11.71 | 37.71 ± 11.55 | 46.55 ± 10.28 | 0.000 |
|
| ||||
| Male | 149 (86.1%) | 115 (89.1%) | 106 (86.4) | 0.497 |
| Femle | 24 (13.9%) | 14 (10.9%) | 20 (13.6) | |
|
| ||||
| No | 127 (73.4%) | 96 (74.4) | 101 (80.2) | 0.373 |
| Yes | 46 (26.6%) | 33 (25.6) | 25 (19.8) | |
|
| ||||
| No | 121 (69.9%) | 88 (68.2) | 91 (70.1) | 0.782 |
| Yes | 52 (30.1%) | 41 (31.8) | 35 (29.9) |
*Student’ t test.
**Chi-square test.
Frequency distributions of polymorphisms among cases and controls
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
|
| ||||||||
| Genotypes | ||||||||
| AA | 90 (71.4) | 84 (65.1) | 116 (67.1) | 1Ref | 1Ref | |||
| AT | 32 (25.4) | 36 (27.9) | 47 (27.2) | 0.781 | 1.086 (0.607-1.943) | 0.588 | 0.863 (0.507-1.470) | |
| TT | 4 (3.2) | 9 (7.0) | 10 (5.8) | 0.481 | 1.458 (0.511-4.159) | 0.264 | 0.505 (0.152-1.675) | |
| Allele | ||||||||
| A | 212 (84.1) | 204 (79.1) | 279 (80.6) | 1Ref | 1Ref | |||
| T | 40 (15.9) | 54 (20.9) | 67 (19.4) | 0.480 | 1.176 (0.750-1.844) | 0.250 | 0.775 (0.505-1.196) | |
| Dominant model AT + TT vs AA | 0.617 | 1.148 (0.668-1.974) | 0.389 | 0.801 (0.483-1.328) | ||||
| Recessive model TT vs AA + AT | 0.505 | 1.421 (0.506-3.991) | 0.291 | 0.526 (0.160-1.730) | ||||
|
| ||||||||
| Genotypes | ||||||||
| AA | 79 (62.7) | 72 (55.8) | 82 (47.4) | 1Ref | 1Ref | |||
| AG | 40 (32.7) | 43 (33.3) | 68 (39.3) | 0.640 | 0.874 (0.498-1.534) | 0.071 | 0.630 (0.381-1.041) | |
| GG | 7 (5.6) | 14 (10.9) | 23 (13.3) | 0.256 | 0.625 (0.278-1.407) | 0.014 | 0.321 (0.130-0.793) | |
| Allele | ||||||||
| A | 198 (78.6) | 187 (72.5) | 232 (67.6) | 1Ref | 1Ref | |||
| G | 54 (21.4) | 71 (27.5) | 111 (32.4) | 0.232 | 0.785 (0.528-1.167) | 0.003 | 0.565 (0.388-0.825) | |
| Dominant model AG + GG vs AA | 0.392 | 0.799 (0.478-1.336) | 0.013 | 0.551 (0.344-0.883) | ||||
| Recessive model GG vs AA + AG | 0.295 | 0.659 (0.301-1.440) | 0.034 | 0.385 (0.159-0.930) | ||||
LC, liver cirrhosis; CHB, chronic hepatitis; Ref, reference; OR, odds ratio; 95% CI, 95% confidence interval.
P value: after logistic regressive analysis by adjusting for confounding factors (age, gender, alcohol consumption, etc.).
Haplotype analysis among +874 T/A and +2109A/G SNPs
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| A+874A+2109 | 148 (57.4) | 186 (53.8) | 0.384 | 1.155 [0.835 ~ 1.599] | 160 (63.4) | 186 (53.8) | 0.019 | 1.485 [1.065 ~ 2.070] |
| A+874G+2109 | 56 (21.7) | 93 (26.8) | 0.148 | 0.756 [0.517 ~ 1.105] | 52 (20.7) | 92 (26.8) | 0.087 | 0.714 [0.485 ~ 1.051] |
| T+874A+2109 | 39 (15.1) | 46 (13.2) | 0.512 | 1.166 [0.735 ~ 1.850] | 38 (15.2) | 45 (13.2) | 0.495 | 1.175 [0.739 ~ 1.868] |
| T+874G+2109 | 15 (5.8) | 21 (6.1) | 0.876 | 0.948 [0.480 ~ 1.872] | 2 (0.7) | 21 (6.1) | 0.001 | 0.106 [0.022 ~ 0.502] |
Genotype frequencies in healthy control subjects in this study and from the HapMap project or previous studies
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
| This study | 173 | 116 (67.1) | 47 (27.2) | 10 (5.8) | 1Ref | 279 (80.6) | 67 (19.4) | 1Ref |
| Korea [ | 201 | 151 (75.1) | 47 (23.4) | 3 (1.5) | 0.043 | 249 (82.5) | 53 (17.5) | 0.553 |
| Brazil [ | 202 | 79 (39.1) | 82 (40.6) | 41 (20.3) | 0.000 | 240 (59.4) | 164 (40.6) | 0.000 |
| India [ | 146 | 52 (35.6) | 77 (52.7) | 17 (11.6) | 0.000 | 181 (62.0) | 111 (38.0) | 0.032 |
| Tunisia [ | 103 | 33 (32.0) | 47 (45.6) | 23 (22.3) | 0.000 | 113 (54.9) | 93 (45.1) | 0.000 |
|
|
|
|
|
|
| |||
| This study | 173 | 112 (64.7) | 52 (30.1) | 9 (5.2) | 1Ref | 232 (67.6) | 111 (32.4) | 1Ref |
| HCB | 45 | 21 (46.7) | 18 (40.0) | 6 (13.3) | 0.040 | 60 (66.7) | 30 (33.3) | 0.008 |
| JPT | 44 | 16 (36.4) | 13 (29.5) | 15 (34.1) | 0.000 | 45 (51.1) | 43 (48.9) | 0.000 |
| CEU | 58 | 23 (39.7) | 31 (53.4) | 4 (6.9) | 0.003 | 77 (66.4) | 39 (33.6) | 0.003 |
| YRI | 59 | 47 (79.7) | 12 (20.3) | 0 (0) | 0.050 | 106 (89.8) | 12 (10.2) | 0.013 |
HCB Han Chinese in Beijing, China, JPT Japanese in Tokyo, Japan, CEU Utah residents with Northern and Western.
European ancestry, YRI Yoruba in Ibadan, Nigeria.